BHC Earnings Date: Feb 17, 2027 (Estimated) — Bausch Health Companies Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is BHC's next earnings date?
Bausch Health Companies Inc. (BHC) is expected to report Q4 2026 earnings on Wednesday, February 17, 2027 at 4:05 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.25 on revenue of $2.80B.
How did BHC do in its last earnings report?
In its most recent report on Oct 28, 2026, Bausch Health Companies Inc. posted EPS of $1.77 versus the $1.25 estimate, a beat of 41.6%. Revenue was $2.94B against a $2.72B estimate. The stock's 1-day post-earnings move was +41.2%.
How much does BHC stock move after earnings?
BHC beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.2% (up or down) in the day after earnings.
About Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
🤖 AI Earnings Analysis
Bausch Health delivered a strong specialty-pharma quarter: revenue rose 10% reported (8% organic) to $2.94B, while adjusted EPS of $1.77 beat estimates by $0.52. Raised guidance and refinancing plus a $50M buyback reinforce improving confidence.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | 1.25 | 1.77 | +41.60% | $2.94B | ✅ Beat | +41.20% | — | — | |
| 2026-07-29 | Q2 2026 | 1.01 | 1.26 | +24.75% | $2.85B | ✅ Beat | +28.85% | +34.40% | +34.62% |
| 2026-04-29 | Q1 2026 | 0.72 | 0.78 | +8.33% | $2.52B | ✅ Beat | +2.33% | +1.07% | -4.11% |
| 2026-02-18 | Q4 2025 | 1.24 | 1.10 | -11.29% | $2.80B | ❌ Miss | -4.20% | -1.29% | -18.74% |
| 2025-10-29 | Q3 2025 | 1.06 | 1.16 | +9.43% | $2.68B | ✅ Beat | +12.03% | +14.92% | +7.63% |
| 2025-07-30 | Q2 2025 | 0.95 | 0.91 | -4.21% | $2.53B | ❌ Miss | -7.82% | -9.86% | +11.89% |
| 2025-04-30 | Q1 2025 | 0.85 | 0.61 | -28.24% | $2.26B | ❌ Miss | +0.00% | -11.32% | -14.53% |
| 2024-08-01 | Q2 2024 | 0.88 | 0.98 | +11.36% | $2.40B | ✅ Beat | +1.16% | -13.43% | -2.65% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $2.94B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 99.0% | $2.91B | +9.6% | — | $2.23B | $2.50B | $2.66B |
| Product and Service, Other | 1.0% | $29.0M | +20.8% | — | $32.0M | $26.0M | $24.0M |
By region
Q4 FY24 · $2.48B total
| Segment | Share | Revenue | YoY | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 |
|---|---|---|---|---|---|---|---|
| United States and Puerto Rico | 62.1% | $1.54B | +5.8% | $1.27B | $1.36B | $1.46B | $1.25B |
| Other Countries | 11.8% | $292.0M | +4.7% | $252.0M | $242.0M | $279.0M | $256.0M |
| CHINA | 5.8% | $145.0M | +15.1% | $114.0M | $113.0M | $126.0M | $97.0M |
| CANADA | 4.4% | $109.0M | +11.2% | $92.0M | $92.0M | $98.0M | $90.0M |
| POLAND | 3.8% | $94.0M | +8.0% | $75.0M | $82.0M | $87.0M | $86.0M |
| MEXICO | 2.7% | $67.0M | -23.9% | $75.0M | $90.0M | $88.0M | $76.0M |
| FRANCE | 2.1% | $52.0M | +15.6% | $63.0M | $49.0M | $45.0M | $61.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.